21 Sep, 2022 · In Press Releases
19 Sep, 2022 · In Press Releases
World’s first soft robotic muscle strengthening system. Developed in collaboration with leading Fortune 500 companies
30 Aug, 2022 · Regulatory information
The board of Bioservo AB (publ) ("Bioservo" or the "Company") today releases the Company's interim report for the second quarter 2022 and new financial targets for 2025 based on the increased interest from industrial segment in the US and the upcoming launch of Carbonhand 2.0 in the health care segment. According to the new targets, Bioservo will reach a revenue of SEK 100 million and a positive cash flow during 2025.
Second quarter in figures
First half-year in figures
Significant events during the period
Events after the end of the period
New financial targets
In the light of the increasing interest in Ironhand 2.0 among industrial customers mainly in the American market and the upcoming commercialization of Carbonhand 2.0 in the healthcare segment, which will begin after the final study results from the iHand study are presented in September 2022, Bioservo's board has resolved on financial targets for 2025. According to the new targets, Bioservo will reach a revenue of SEK 100 million and positive cash flow during 2025.
For further information please contact:
Petter Bäckgren, CEO
+46 8 21 17 10
Mikael Wester, Marketing Director
+46 8 21 17 10
The information in this press release is such that Bioservo Technologies AB (publ) is obliged to publish in accordance with EU Regulation on Market Abuse (MAR). The information was submitted for publication through the agency of above contact persons for publication on August 30, 2022 at 05:35 p.m. CEST.
About Bioservo Technologies
Bioservo Technologies AB (publ) is a world leading company in wearable muscle strengthening systems for people in need of extra strength and endurance. All our innovative products and systems are designed to keep people strong, healthy, and efficient. The company has a unique global position within soft exoskeleton technology for the hand, both for industrial applications to improve the health for workers and to improve quality of life for people with reduced muscle strength. Bioservo Technologies was founded in 2006 in collaboration between researchers at the Royal Institute of Technology and a doctor at Karolinska University Hospital. Bioservo Technologies is a Swedish public limited company with headquarters in Stockholm.
FNCA Sweden AB, +46(0)8-52800399, email@example.com is the company’s Certified Adviser on Nasdaq First North
For more information, please visit www.bioservo.com